IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 926-950 out of 1237.

<< < 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 > >>

Public Release: 4-Jun-2014
PLOS ONE
Mayo Clinic moves small-molecule drugs through blood-brain barrier
Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications.

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 4-Jun-2014
Cancer Discovery
Four new genes confirmed to increase familial breast cancer risk
Four new genes have been added to the growing list of those known to cause increased breast cancer risk when mutated through the efforts of researchers at Huntsman Cancer Institute at the University of Utah, who lead an international consortium working to find more gene mutations that cause inherited breast cancer susceptibilities.
National Institutes of Health, Breast Cancer Family Registry, Huntsman Cancer Foundation

Contact: Linda Aagard
linda.aagard@hci.utah.edu
801-587-7639
University of Utah Health Sciences

Public Release: 3-Jun-2014
Hepatology
Liver cancer vaccine effective in mice
Tweaking a protein expressed by most liver cancer cells has enabled scientists to make a vaccine that is exceedingly effective at preventing the disease in mice.
NIH/National Cancer Institute

Contact: Toni Baker
tbaker@gru.edu
706-721-4421
Medical College of Georgia at Georgia Regents University

Public Release: 3-Jun-2014
Nature Medicine
'Liquid biopsy' offers new way to track lung cancer
Research carried out at Cancer Research UK's Manchester Institute, based at The University of Manchester -- part of the Manchester Cancer Research Centre -- has looked at the potential of using circulating tumor cells -- cells that have broken off from the tumor and are circulating in the blood -- to investigate a patient's disease in a minimally invasive manner.
Cancer Research UK

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester

Public Release: 3-Jun-2014
Nature Communications
Tumor chromosomal translocations reproduced for the first time in human cells
Scientists from the Spanish National Cancer Research Centre and the Spanish National Cardiovascular Research Centre have been able to reproduce, for the first time in human cells, chromosomal translocations associated with two types of cancer: acute myeloid leukemia and Ewing's sarcoma. The discovery, published today in the journal Nature Communications, opens the door to the development of new therapeutic targets to fight these types of cancer.

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 3-Jun-2014
CLEO: 2014
Lasers and night-vision technology help improve imaging of hidden lymphatic system
Detecting lymphedema early, before swelling occurs, would lead to better outcomes for patients, but the major barrier preventing early diagnosis is the lack of high-resolution imaging techniques that can resolve these tiny vessels. Recently, a team of researchers at UTHealth Medical School has developed a new technology that can non-invasively image the human lymphatic system. A fluorescent dye and commercially-available laser diode and military-grade night vision devices are used to visualize the lymphatic capillaries.

Contact: Lyndsay Meyer
lmeyer@osa.org
202-416-1435
The Optical Society

Public Release: 3-Jun-2014
Science Signaling
New insight into drug resistance in metastatic melanoma
Now researchers from the Cancer Research UK Manchester Institute at The University of Manchester -- part of the Manchester Cancer Research Centre -- have explored what happens in melanoma cells following inhibition of BRAF.
Cancer Research UK

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester

Public Release: 3-Jun-2014
Cancer
Screening has prevented half a million colorectal cancers
An estimated half a million cancers were prevented by colorectal cancer screening in the United States from 1976 to 2009, report researchers from the Cancer Outcomes, Public Policy, and Effectiveness Research Center at Yale Cancer Center. Their study appears in the journal Cancer. During this more than 30-year time span, as increasing numbers of men and women underwent cancer screening tests -- including fecal occult blood testing, sigmoidoscopies, and colonoscopies -- colorectal cancer rates declined significantly, the researchers found.
Medtronic, Johnson & Johnson, Natoinal Institutes of Health

Contact: Helen Dodson
helen.dodson@yale.edu
203-436-3984
Yale University

Public Release: 3-Jun-2014
Technology
New device isolates most aggressive cancer cells
Not all cancer cells are created equal -- some stay put in the primary tumor, while others move and invade elsewhere. A major goal for cancer research is predicting which cells will metastasize, and why. A Cornell cancer research team is taking a new approach to screening for these dangerous cells, using a microfluidic device they invented that isolates only the most aggressive, metastatic cells.
NIH/National Cancer Institute

Contact: Melissa Osgood
mmo59@cornell.edu
607-255-2059
Cornell University

Public Release: 3-Jun-2014
JAMA
Moffitt researchers develop process to help personalize treatment for lung cancer patients
Moffitt Cancer Center researchers, in collaboration with the Lung Cancer Mutation Consortium, have developed a process to analyze mutated genes in lung adenocarcinoma to help better select personalized treatment options for patients. Adenocarcinoma is the most common type of lung cancer in the United States with approximately 130,000 people diagnosed each year.
NIH/National Cancer Institute

Contact: Kim Polacek
Kim.Polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 3-Jun-2014
Nucleic Acids Research
Deeper than ancestry.com, 'EvoCor' identifies gene relationships
A team led by Gregorio Valdez of the Virginia Tech Carilion Research Institute has designed a search engine that identifies genes that are functionally linked. The discovery may lead to ways to treat diseases that have a genetic component, such as cancer or Alzheimer's.

Contact: Paula Byron
pbyron@vt.edu
540-526-2027
Virginia Tech

Public Release: 3-Jun-2014
Journal of Clinical Endocrinology and Metabolism
Experts recommend blood, urine testing to diagnose rare adrenal tumors
The Endocrine Society today issued a Clinical Practice Guideline for the diagnosis and treatment of two types of rare adrenal tumors -- pheochromocytomas and paragangliomas -- that can raise the risk of cardiovascular disease and even death if left untreated.

Contact: Jenni Glenn Gingery
jgingery@endocrine.org
202-971-3655
The Endocrine Society

Public Release: 3-Jun-2014
Journal of the National Cancer Institute
Study: New test predicts if breast cancer will spread
A test that counts the number of locations in tumor specimens where tumor cells may invade blood vessels predicted the risk of distant spread, or metastasis, for the most common type of breast cancer.
NIH/National Cancer Institute

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine

Public Release: 2-Jun-2014
Nature Genetics
BRCA2 gene now connected to lung cancer, doubling a smoker's risk
New research confirms a vulnerability to lung cancer can be inherited and implicates the BRCA2 gene as harboring one of the involved genetic mutations. An international consortium of scientists including investigators used integrated results from the 1000 Genomes Project with genetics studies of lung cancer to complete the investigation published on June 1, 2014, in Nature Genetics.
National Institutes of Health

Contact: Robin Dutcher
Robin.dutcher@hitchcock.org
603-653-9056
The Geisel School of Medicine at Dartmouth

Public Release: 2-Jun-2014
ASCO 50th Annual Meeting
New therapies harness power of the immune system against cancer
New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology. These treatments -- used alone or in combination -- fight cancer by activating and amplifying the body's immune response to the disease.

Contact: Kate Blackburn
Kate.Blackburn@asco.org
312-949-3232
American Society of Clinical Oncology

Public Release: 2-Jun-2014
ASCO 50th Annual Meeting
Myriad myPath melanoma test improves the reliability of melanoma diagnosis
Results from a pivotal clinical validation study of the Myriad myPath Melanoma test at the 2014 American Society of Clinical Oncology meeting show that it accurately differentiates malignant melanoma from benign skin lesions with a high level of accuracy and helps physicians deliver a more objective and confident diagnosis for patients. The Myriad myPath Melanoma test is a unique test of 23 genes that provides valuable, additive diagnostic information unavailable from any other method.

Contact: Ronald Rogers
rrogers@myriad.com
908-285-0248
Myriad Genetics, Inc.

Public Release: 2-Jun-2014
ASCO 50th Annual Meeting
Long-term results encouraging for combination immunotherapy for advanced melanoma
The first long-term follow-up results from a phase 1b immunotherapy trial combining drugs for advanced melanoma patients has shown encouraging results -- long-lasting with high survival rates -- researchers report. First author Mario Sznol, M.D., professor of medical oncology at Yale Cancer Center, is presenting the updated data at the 2014 annual conference of the American Society of Clinical Oncology in Chicago.
Bristol-Myers Squibb, Ono Pharmaceutical Company

Contact: Vicky Agnew
vicky.agnew@yale.edu
843-697-6208
Yale University

Public Release: 2-Jun-2014
Journal of Clinical Oncology
Expanded health coverage may improve cancer outcomes in young adults, study suggests
Young adults who lack health care insurance are more likely to be diagnosed in advanced stages of cancer and have a higher risk of death, according to a study from Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School.
Heritage Medical Research Institute

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute

Public Release: 2-Jun-2014
Nature Biotechnology
DREAM project crowdsources answer to cancer cell drug sensitivities
A study published June 1 in the journal Nature Biotechnology describes the results of an open challenge to predict which breast cancer cell lines will respond to which drugs, based only on the sum of cells' genomic data. The winning entry, from the Helsinki Institute for Information Technology, was 78 percent accurate in identifying sensitive versus resistant cell lines, and was one of 44 algorithms submitted by groups from around the world.
National Cancer Institute, National Institutes of Health

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 2-Jun-2014
Blood
One in 4 children with leukemia not taking maintenance medication, study shows
An estimated 25 percent of children in remission from acute lymphocytic leukemia are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published online in Blood, the Journal of the American Society of Hematology.

Contact: Amanda Szabo
aszabo@hematology.org
202-552-4914
American Society of Hematology

Public Release: 2-Jun-2014
Genes & Development
Stopping the spread of breast cancer
Scientists have discovered a new pathway that can stop breast cancer cells from spreading. Working with human cancer cells and a mouse model of breast cancer, scientists identified a new protein that plays a key role in reprogramming cancer cells to migrate and invade other organs. When that protein is removed from cancer cells in mice, the ability of the cells to metastasize to the lung is dramatically decreased.
National Institutes of Health

Contact: Marla Paul
marla-paul@northwestern.edu
312-503-8928
Northwestern University

Public Release: 2-Jun-2014
Journal of Clinical Investigation
JCI online ahead of print table of contents for June 2, 2014
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers published online, June 2, 2014 in the JCI: 'Mucin concentration contributes to a sticky situation in cystic fibrosis,' 'Engineered aptimer targets malignant and tumor-associated T cells,' 'NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF-κB,' 'Myosin Vb uncoupling from RAB8A and RAB11A elicits microvillus inclusion disease,' 'Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation,' and more.

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 2-Jun-2014
International Journal of Radiation Oncology Biology Physics
Gene therapy combined with IMRT found to reduce recurrence for select prostate cancer patients
Combining oncolytic adenovirus-mediated cytotoxic gene therapy with intensity modulated radiation therapy reduces the risk of having a positive prostate biopsy two years after treatment in intermediate-risk prostate cancer without affecting patients' quality of life.

Contact: Brittany Ashcroft
press@astro.org
703-839-7336
American Society for Radiation Oncology

Public Release: 2-Jun-2014
Journal of Clinical Oncology
Study finds risk of recurrence low in smallest HER2+ breast cancer tumors
Patients with specific HER2+ breast cancer tumors had a low risk of the cancer recurring five years after diagnosis, even without chemotherapy or treatment with a common antibody, according to a Kaiser Permanente study published in the Journal of Clinical Oncology.

Contact: Vincent Staupe
vstaupe@golinharris.com
415-318-4386
Kaiser Permanente

Public Release: 2-Jun-2014
Annals of Internal Medicine
Nutrition experts: Debate over value of vitamin, mineral supplements is far from over
Researchers have taken issue with recent claims that 'the case is closed' on whether or not a multivitamin/mineral supplement should be taken by most people to help obtain needed micronutrients.

Contact: Balz Frei
balz.frei@oregonstate.edu
541-737-5078
Oregon State University

Showing releases 926-950 out of 1237.

<< < 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 > >>

  Search News Releases

     

 

EurekAlert!